Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm
暂无分享,去创建一个
Orla Hardiman | A. Chiò | O. Hardiman | P. Bede | N. Pender | A. Montuschi | M. Elamin | Marwa Elamin | Adriano Chio | Peter Bede | Niall Pender | Anna Montuschi
[1] M. York,et al. Detecting frontotemporal dysfunction in ALS: Utility of the ALS Cognitive Behavioral Screen (ALS-CBS™) , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[2] A. Al-Chalabi,et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. , 2002, Neurology.
[3] Adriano Chiò,et al. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. , 2007, Current medicinal chemistry.
[4] O. Hardiman,et al. Cognitive changes predict functional decline in ALS , 2013, Neurology.
[5] J. Cedarbaum,et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.
[6] P. Sham,et al. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis , 2002, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[7] A. Al-Chalabi,et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study , 2012, The Lancet Neurology.
[8] O. Hardiman,et al. Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives , 2011, BMJ Supportive & Palliative Care.
[9] Adriano Chiò,et al. The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials , 2011, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[10] S. Appel,et al. Predictability of disease progression in amyotrophic lateral sclerosis , 2006, Muscle & nerve.
[11] Adriano Chiò,et al. Acute migraine treatment with droperidol , 2003, Neurology.
[12] Chris Shaw,et al. PROGNOSTIC CATEGORIES FOR AMYOTROPHIC LATERAL SCLEROSIS , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[13] G. Filippini,et al. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[14] R. Sica,et al. Regional spread pattern predicts survival in patients with sporadic amyotrophic lateral sclerosis , 2012, European journal of neurology.
[15] L. Goldstein,et al. Cognitive deficits in non-demented amyotrophic lateral sclerosis patients: a neuropsychological investigation , 1995, Journal of the Neurological Sciences.
[16] J. Slattery,et al. The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register , 1993, Journal of Neurology.
[17] E. Beghi,et al. Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[18] A. Chiò,et al. Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV , 2012, Neurology.
[19] S. Appel,et al. Amyotrophic lateral sclerosis: early predictors of prolonged survival , 2006, Journal of Neurology.
[20] A. Chiò,et al. Epidemiology of ALS in Italy , 2009, Neurology.
[21] J. Martí-Fàbregas,et al. [Prognostic factors in amyotrophic lateral sclerosis]. , 1996, Neurologia.
[22] D. Morris,et al. Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing , 2013, Journal of Medical Genetics.
[23] L. H. van den Berg,et al. Lifetime occupation, education, smoking, and risk of ALS , 2007, Neurology.
[24] Bryan J. Traynor,et al. An outcome study of riluzole in amyotrophic lateral sclerosis , 2003, Journal of Neurology.
[25] M. Swash,et al. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[26] O. Hardiman,et al. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004 , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[27] V. Meininger,et al. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole , 2005, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[28] Adriano Chiò,et al. Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[29] O. Combarros,et al. Motor neuron disease in Cantabria , 1988, Acta neurologica Scandinavica.
[30] O. Hardiman,et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study , 2011, Journal of Neurology, Neurosurgery & Psychiatry.
[31] M. Naumann,et al. Disease progression in amyotrophic lateral sclerosis: Predictors of survival , 2002, Muscle & nerve.
[32] C. Ki,et al. Spectrum of Cognitive Impairment in Korean ALS Patients without Known Genetic Mutations , 2014, PloS one.
[33] Elaine Niven,et al. Screening for cognition and behaviour changes in ALS , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[34] O. Hardiman,et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia , 2011, Neurology.
[35] T. Hanafusa,et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS , 2006, Neurology.